Comparative Pharmacology

Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Electrolyte

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Potassium chloride provides potassium ions for maintenance of electrolyte balance and normal cellular function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.

Clinical Dosing

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Intravenous infusion. The typical adult dose is 20-40 mEq of potassium per day, administered as an infusion rate not exceeding 10 mEq/hour or 0.5 mEq/kg/hour. Concentration is 0.11% KCl (1.46 mEq/L) provided in 0.9% NaCl.

Direct Interaction

None Documented